Editorial Perspectives On Patient Recruitment

  1. Humans And Machines Will Partner For Better Outcomes 6/3/2019

    Dr. Emmanuel Fombu spends a lot of time thinking about healthcare. He’s a trained physician and currently leads global strategy and digital innovation at Johnson & Johnson. He would like to see better roadmaps in healthcare that lead us to determining a patient’s level of health. Currently, your doctor asks a question, you supply an answer, and this begins the process of trying to figure out what might be wrong with you.  

  2. AI Speeds Patient Recruitment At Health Quest 5/23/2019

    Artificial intelligence (AI) has the potential to disrupt and revolutionize many aspects of clinical trials. One area in which it is already making an impact is patient recruitment. Mining electronic medical records (EMRs) for patients meeting inclusion and exclusion criteria can be tedious and time-consuming work but is a chore that seems ideal for an AI solution.

  3. Patient Centricity And Social Media Are Changing Patient Recruitment 4/18/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Patient recruitment remains a challenge that pharma must work to overcome.  

  4. Alzheimer's Disease Trials: Where Do We Go From Here? 4/9/2019

    The Alzheimer’s disease space is not an easy one for pharma companies to navigate. In 2018 alone, Lundbeck, Takeda, Merck, Janssen, AstraZeneca, and Eli Lilly and Company all faced setbacks or poor trial results. Unfortunately, few spaces in the life sciences have fathered failure to the extent that experimental Alzheimer’s drugs have. 

  5. 4 Challenges To Overcome In Rare Disease Trials 3/28/2019

    Albireo Pharma is a clinical-stage biopharmaceutical company that was launched in 2008. One of the company’s more promising assets, A4250, is a novel bile acid modulator that has been in development for rare cholestatic liver diseases. The product, which acts locally in the gut, can effectively drain excess bile acids that get stuck in a patient’s liver. In conducting trials with pediatric patients in this space, Albireo faces four challenges common to developers of pediatric rare disease drugs.

  6. Fix Patient Recruitment By Learning From Service-Based Companies 3/7/2019

    How is the industry changing its perspective on patient recruitment? Maura Snyder, director of Clinical Insights and Experience at Janssen, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it. 

  7. How Academia, Physicians, And Patient Groups Will Impact Patient Recruitment 2/27/2019

    Thirty years ago, patient recruitment was a challenge for pharma companies. Today the patient participation rate in trials still hovers around five percent and is not expected to improve anytime soon. Mary Rose Keller, VP of Clinical Operations at Heron Therapeutics, shares some of her thoughts on the recruitment challenge and what pharma must do to overcome it. 

  8. Clinical Trial Consortium Aims To Eliminate Inefficiency 11/13/2018

    On March 1, 2018, the Partners in Innovation, Education, and Research Consortium™ (PIER) became an LLC in the State of Delaware. The six founding members of PIER (Jefferson Health, Atlantic Health System, Drexel University, Einstein Healthcare Network, Geisinger Health System, and Main Line Health) hope to bring efficiencies and cost reductions to clinical research.

  9. Traditional Digital Advertising Rules Don't Apply To Patient Recruitment 10/31/2018

    Syneos Health has released the results of a study conducted to gather real-world patient insights into the effectiveness of digital advertising to assist with clinical trial recruitment.

  10. A New Immunotherapy Paradigm: It's Not Just For Cancer Anymore 10/19/2018

    When Bruce Gillis, CEO of EpicGenetics, decided to look into fibromyalgia, he drew blood from 17 patients and analyzed 35 different immune system factors. When compared to a control group, he was astounded by the results. There was a huge disparity between the immune system markers for the 17 patients and those of the control group. That launched his quest for a cure.